SCHEMBL6519769

SCHEMBL6519769

O=c1[nH]c2nccc(C#Cc3ccsc3)c2c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 17/20 0.50
AURKB Q96GD4 13/20 0.50
PARP1 P09874 1/20 0.43
CYP2A6 P11509 1/20 0.41
MAPK13 O15264 1/20 0.40
CHEK2 O96017 1/20 0.40
NTRK1 P04629 1/20 0.40
RET P07949 1/20 0.40
HCK P08631 1/20 0.40
FGFR1 P11362 1/20 0.40
FLT4 P35916 1/20 0.40
LIMK1 P53667 1/20 0.40
SIK1 P57059 1/20 0.40
TNK2 Q07912 1/20 0.40
WNK3 Q9BYP7 1/20 0.40
ALK Q9UM73 1/20 0.38
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6517228 0.85 AURKA (0.57) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6527193 0.81 AURKA (0.62) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6525060 0.81 AURKA (0.52) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6521997 0.81 AURKA (0.52) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6517875 0.78 PTK6 (0.50) AURKAAURKBPARP1ALKNPC1
SCHEMBL6519094 0.78 AURKA (0.54) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6525830 0.78 AURKA (0.55) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6521766 0.78 AURKA (0.51) AURKAAURKBPARP1CHEK2RET
SCHEMBL6519144 0.78 AURKA (0.55) AURKAAURKBPARP1MAPK13CHEK2
SCHEMBL6522991 0.78 AURKA (0.49) AURKAAURKBPARP1MAPK13CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885AURKB 487/4885PARP1 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.